Doctors Can Halve Radiation Dose for Hodgkin's Lymphoma

Halving the usual dose of radiation and combining it with chemotherapy can produce high survival rates in people with early-stage Hodgkin's lymphoma.



That finding was presented Monday by German researchers at the American Society for Therapeutic Radiology and Oncology (ASTRO) annual meeting in Denver, Colorado.



The researchers noted that, if caught early, Hodgkin's lymphoma can be cured and most patients live for many years after their diagnosis. However, they often have to cope with side effects of radiation treatment.



The researchers wanted to examine whether those side effects could be reduced by decreasing the amount of radiation needed to treat patients.



The four-year study of 1,131 patients looked at whether reducing the amount of radiation (from 30 Gy to 20 Gy) and combining it with chemotherapy would cure the patients. More than 98 percent of the patients who received this treatment experienced complete remission, while 13 patients died from Hodgkin's lymphoma during the study, the researchers said.



"Although this was an interim study, the results are very encouraging that we can cure patients with early stage Hodgkin's lymphoma of their cancer while reducing the amount of radiation we give them, thus allowing them to have a higher quality of life after treatment," study author Dr. Hans Theodor Eich, a radiation oncologist at the University of Cologne, said in a prepared statement.

Blog Category: 

More Articles

More Articles

Amazon.com is pleased to have the Lymphoma Information Network in the family of Amazon.com associates. We've agreed to ship items...

The question ought to be what are myelodysplastic syndromes (MDS), since this is a group of similar blood and bone marrow diseases that...

Merkel Cell Carcinoma (MCC) is a very rare and aggressive skin cancer that usually develops when a person is in his or her 70s. It is...

Radiation Therapy Topics

...

At some point, the Seattle biotech company Cell Therapeutics Inc (CTI) should earn an entry in the Guinness Book of World Records for utter and...

Site Beginnings

This site was started as Lymphoma Resource Page(s) in 1994. The site was designed to collect lymphoma...

Three papers appearing in the journal Blood and pointing towards a regulator-suppressor pill could offer hope to blood cancer...

The US Food and Drug Administration (FDA) has granted a third so-called Breakthrough Therapy Designation for the investigational oral...

The US Food and Drug Administration today has approved an expanded use of Imbruvica (ibrutinib) in patients with...

The U.S. Food and Drug Administration has announced that it has granted "Breakthrough Therapy Designation" for the investigational agent...

According to a new study published in the Proceedings of the National Academy of Sciences, a team from the University of California, San...

Pharmacyclics has announced that the company has submitted a New Drug Application (NDA) to the US Food and Drug Administration (FDA) for...

New research suggests that frontline radioimmunotherapy...

Gilead Sciences has announced results of the company's Phase II study of its investigational compound idelalisib, an oral inhibitor of...

Sitemap